MiMedx Group, Inc.
mimedx.comWhat Do They Do?
Sells products clinicians use to treat chronic and hard-to-heal wounds, plus tissue products for surgical procedures, to hospitals, clinics and physician offices, including federal health facilities.
10-K for FY2025, filed Feb 25, 2026Today, our product portfolio is routinely used to help clinicians treat patients suffering from chronic and other hard-to-heal wounds, in…View ↗
In addition to our presence in the AWC settings, our products are also used in a variety of surgical settings, and our strategic goals…View ↗
Our direct sales team includes field sales representatives and field sales management, who call on hospitals, wound care clinics, physician…View ↗
How Do They Make Money?
Customers buy products directly or through independent distributors. MiMedx invoices shipped orders when they ship; products held at a customer's site are sold when implanted, and payment is typically due 30 to 60 days after title passes.
10-K for FY2025, filed Feb 25, 2026The Company sells its products primarily to individual customers and independent distributors (collectively referred to as “customers”).…View ↗
The Company recognizes revenue as performance obligations are fulfilled, which generally occurs upon the shipment of product to the…View ↗
The Company’s payment terms for customers are typically 30 to 60 days from receipt of title of the goods.View ↗
-
10-K for FY2025, filed Feb 25, 2026
FY2025 revenue by product or service ↗
$418.6M
-
10-K for FY2025, filed Feb 25, 2026
$418.6M ↗
| Segment | Share | Revenue | How money arrives |
|---|---|---|---|
|
Wound
Sold outright
10-K for FY2025, filed Feb 25, 2026 |
66%
FY2022: 66%
|
Wound, FY2025
$276.3M Sources
|
Sold outright |
|
Surgical
Sold outright
10-K for FY2025, filed Feb 25, 2026 |
34%
FY2022: 34%
|
Surgical, FY2025
$142.3M Sources
|
Sold outright |
Who Are Their Customers?
The direct sales team calls on hospitals, wound care clinics, physician offices and federal health facilities. Independent sales agents and distributors provide additional customer access, and distributors resell products to providers and end users.
10-K for FY2025, filed Feb 25, 2026
Do Revenues Turn Into Profits?
Yes. It kept 12 cents of every revenue dollar as net income in FY2025.
10-K for FY2025, filed Feb 25, 2026
How Are They Changing?
- Net income
-
Sources
10-Q for Q2 FY2026, filed Jul 29, 2026
−$14.8MView ↗
- ▼ Now a loss
- vs $9.6M in Q2 FY2025
10-Q for Q2 FY2026, filed Jul 29, 2026
Open tableView ↗
-
Jul 29, 2026
Agreed to acquire Sanara MedTech and reiterated its sales outlook
The proposed cash-and-stock deal is expected to close by year-end, subject to approvals; the company kept its $260 to $290 million 2026 sales outlook.
Sources
8-K, filed Jul 29, 2026
For 2026, MIMEDX continues to expect 2026 net sales to be in a range of $260 to $290 million. 2026 Adjusted EBITDA is expected to approach…View ↗
Growing. Revenue grew 73% in 4 years, from $242M in FY2021 to $418.6M in FY2025, about 15% a year.
Broader product portfolio
The business has expanded beyond human placental allografts to include an animal-derived collagen product and additional wound-care products sold under distribution agreements.
10-K for FY2022, filed Feb 28, 2023 10-K for FY2025, filed Feb 25, 2026MIMEDX is a pioneer and leader in placental biologics, developing and distributing placental tissue allografts with patent-protected…View ↗
Since its inception, MIMEDX has focused on leading the industry with its deep expertise, unmatched peer-reviewed scientific and clinical…View ↗
In 2024, we obtained the exclusive rights for and launched our first xenograft product and first U.S. Food & Drug Administration (“FDA”)…View ↗
In 2025 and early 2026, we entered into exclusive distribution agreements for several products, including:View ↗
Who Do They Compete With?
Competes with Integra LifeSciences Holdings, Organogenesis, and Smith & Nephew
10-K for FY2025, filed Feb 25, 2026Our main publicly-traded competitors in the skin substitute market include Integra LifeSciences Holdings Corporation, Organogenesis, Inc.…View ↗
Loading...
